Antony David

Federal Circuit Holds That Claims Directed To A Specific Method Of Treatment For Specific Patients Using A Specific Compound At Specific Doses To Achieve A Specific Outcome Satisfy 35 U.S.C. §101

Federal Circuit Affirms Patent-Ineligibility Of Diagnostic Method Claims

U.S. Jury Upheld Validity Of Two Patents For Amgen Inc's Cholesterol-Lowering Drug Repatha® (Evolocumab)

United States District Court For The District Of New Jersey Invalidates All Asserted Claims Of US Patent No. 8822438 For Prostate Cancer Drug Zytiga (Abiraterone Acetate)

Federal Circuit Rules 180-Day Post-Licensure Notice Is Mandatory In Biosimilar Litigation